InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update

InMed Pharmaceuticals Inc. VANCOUVER, British Columbia, Sept. 23, 2022 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today reported financial results for the fiscal year ended June 30, 2022. Conference Call […]

Relief Reports Half-Year 2022 Results and Provides Corporate Update

GENEVA, SWITZERLAND / ACCESSWIRE / September 15, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (“Relief”), a Swiss, commercial-stage biopharmaceutical company seeking to provide patients therapeutic benefit from selected specialty, rare and ultra-rare diseases with high unmet need, today reported its results for the half-year ended June 30, 2022 and provided […]

Eastman Provides Update on Third-Quarter 2022 Economic Results

KINGSPORT, Tenn., September 13, 2022–(Organization WIRE)–Eastman Chemical Firm (NYSE:EMN) provided an update on its 3rd-quarter 2022 monetary final results. Third-quarter 2022 altered earnings for each share (EPS) are predicted to be somewhere around $2.00. Prior expectations were being for good progress when compared to third-quarter 2021 altered EPS of $2.46. […]

Discovery Reports Q2 2022 Financial Results and Update

Discovery Silver Corp. TORONTO, Aug. 25, 2022 (GLOBE NEWSWIRE) — Discovery Silver Corp. (TSX-V: DSV, OTCQX: DSVSF) (“Discovery” or the “Company”) is pleased to announce its financial results for the three months ended June 30, 2022 (“Q2 2022”) and provide a summary of key events for the quarter, and subsequent […]

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2022 Financial Results

Elwanda Tulloch

Quoin Pharmaceuticals, Inc. Initiates clinical trial evaluating lead product candidate, QRX003 for Netherton SyndromeExpands number of commercial partnerships to eight, covering 60 countriesSigns Research Agreement to develop a product for the treatment of scleroderma Closes $16.8 million public offering, with net proceeds of approximately $15.0 million ASHBURN, Va., Aug. 18, […]

Subscribe US Now